# Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

Study · id `cardio:ct-nct03340493` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03340493](<https://clinicaltrials.gov/study/NCT03340493>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03340493

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT03340493. Randomized; single masking; primary purpose treatment. Start 2017-12-06 (actual); primary completion 2019-07-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT03340493, source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)
- Started: 2017-12-06 (actual) (ClinicalTrials.gov record NCT03340493, source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)
- Primary completion: 2019-07-23 (actual) (ClinicalTrials.gov record NCT03340493, source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)
- Completion: 2020-02-01 (actual) (ClinicalTrials.gov record NCT03340493, source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)
- Countries: Australia; New Zealand (ClinicalTrials.gov record NCT03340493, source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03340493-2020-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
- Condition: Ischemic Stroke
- Intervention (Drug): Tenecteplase
- Lead sponsor: Neuroscience Trials Australia
- Lead sponsor class: OTHER
- Collaborator: The Florey Institute of Neuroscience and Mental Health
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Neuroscience Trials Australia (`cardio:org-neuroscience-trials-australia`)
- Registry lists this organization as a collaborator: The Florey Institute of Neuroscience and Mental Health (`cardio:org-the-florey-institute-of-neuroscience-and-mental-health`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial (`cardio:pubmed-32078683`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study (`cardio:pubmed-31564231`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a3cfc0491cf1dce28a1242ca226f23f4a7dcd26ddf3ca13cfb3b24ca68e7f9d1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
